Veru

Veru EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Veru (VERU) as of Oct 30, 2026 is -1.59. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -1.08 — a change of 47.35% (lower).

EV/EBIT

-1.59

YoY

47.35%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Veru is 2025 -1.59 . EV/EBIT (Enterprise Value to EBIT) of Veru was 2024 -1.08 . It decreases by 47.35% lower compared to the previous year.

The Veru EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-6.11 USD
Jan 1, 2020
-2.67 USD
Jan 1, 2021
4.31 USD
Jan 1, 2022
-0.47 USD
Jan 1, 2023
-0.42 USD
Jan 1, 2024
-1.08 USD
Jan 1, 2025
-1.59 USD
Jan 1, 2026 (e)
-3.08 USD
The Veru EV/EBIT history
YEAREV/EBITYoY
est-3.08+93.86%
-1.59+47.35%
-1.08+157.16%
-0.42-11.26%
-0.47-110.95%
4.31-261.75%
-2.67-56.36%
-6.11+212.65%
-1.95-57.48%
-4.60-135.28%
13.03+119.26%
5.94-40.71%
10.02-74.51%
39.32+32.79%
29.61-52.36%
62.16+4.21%
59.65+43.87%
41.46-15.51%
49.07-63.50%
134.42-49.55%
266.43—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Veru Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Veru's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Veru's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Veru's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Veru grows earnings faster than its peers.

Veru Stock analysis

What does Veru do? Veru, Inc. generates revenue primarily through its Commercial segment, which focuses on FC2, a female condom product designed to prevent unintended pregnancy and sexually transmitted infections. The company's Research and Development segment develops multiple oncology and urology drug products, including VERU-111, VERU-100, and Zuclomiphene Citrate, targeting prostate cancer and breast cancer. These pipeline products are under clinical development and not yet commercialized. The Commercial segment's FC2 is sold to healthcare providers, distributors, and consumers seeking contraceptive and STI protection solutions. The Research and Development segment's drug candidates are not yet marketed, so revenue from this segment currently comes from partnerships or grants, though the business description does not specify such sources. Veru, Inc. operates in two segments: Commercial and Research and Development. The Commercial segment's FC2 product is the company's sole marketed product, while the Research and Development segment focuses on developing VERU-111, VERU-100, and Zuclomiphene Citrate for prostate cancer and breast cancer treatment. VERU-111 targets microtubules by crosslinking and disrupting alpha and beta tubulin subunits, and VERU-100 is a peptide formulation addressing limitations of androgen deprivation therapies for advanced prostate cancer. Zuclomiphene Citrate is part of the prostate cancer pipeline but lacks further detail in the description. The company's revenue streams are currently limited to FC2 sales in the Commercial segment, with no indication of revenue from the Research and Development segment's pipeline products. FC2 is marketed to healthcare providers, distributors, and end consumers for contraceptive and STI prevention purposes. The business description does not mention any other products, partnerships, or revenue sources beyond FC2 and the R&D pipeline. Veru is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Veru stock

EV/EBIT (Enterprise Value to EBIT) of Veru is -1.59 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Veru changed from -1.08 to -1.59, representing a 47.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Veru since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Veru with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Veru

All Key Metrics — Veru